Designing Risk Detection Metrics for Risk-Based Monitoring
Triumph are proud to release the following position paper: Designing Risk Detection Metrics for Risk-Based Monitoring
Triumph are proud to release the following position paper:
Designing Risk Detection Metrics for Risk-Based Monitoring
To download Triumph's position paper, please click on the link to the Triumph website and go to the Risk-Based Monitoring page: http://www.triumphconsultancy.co.uk/
Triumph are going to be presenting their approach and new operational system, Visual OPRA, at the CBI Risk-Based Monitoring in Clinical Studies 2013 conference October 24-25, Philadelphia, PA.
For more info on the CBI conference please visit our Events page on our website at www.triumphconsultancy.co.uk, or contact us as at [email protected]
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
